Free Trial

Compass Therapeutics (CMPX) Competitors

$1.00
+0.06 (+6.38%)
(As of 07/22/2024 ET)

CMPX vs. PCB, TCBX, AVXL, FATE, PROK, VYGR, AURA, KYTX, OCGN, and CCCC

Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include PCB Bancorp (PCB), Third Coast Bancshares (TCBX), Anavex Life Sciences (AVXL), Fate Therapeutics (FATE), ProKidney (PROK), Voyager Therapeutics (VYGR), Aura Biosciences (AURA), Kyverna Therapeutics (KYTX), Ocugen (OCGN), and C4 Therapeutics (CCCC).

Compass Therapeutics vs.

PCB Bancorp (NASDAQ:PCB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.

PCB Bancorp presently has a consensus price target of $17.00, indicating a potential downside of 5.87%. Compass Therapeutics has a consensus price target of $9.00, indicating a potential upside of 800.00%. Given PCB Bancorp's stronger consensus rating and higher probable upside, analysts clearly believe Compass Therapeutics is more favorable than PCB Bancorp.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PCB Bancorp
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Compass Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

33.0% of PCB Bancorp shares are held by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are held by institutional investors. 25.0% of PCB Bancorp shares are held by company insiders. Comparatively, 30.0% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

PCB Bancorp has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

PCB Bancorp has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than PCB Bancorp, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PCB Bancorp$161.86M1.59$30.70M$1.7510.32
Compass TherapeuticsN/AN/A-$42.49M-$0.36-2.78

Compass Therapeutics received 13 more outperform votes than PCB Bancorp when rated by MarketBeat users. Likewise, 73.53% of users gave Compass Therapeutics an outperform vote while only 48.00% of users gave PCB Bancorp an outperform vote.

CompanyUnderperformOutperform
PCB BancorpOutperform Votes
12
48.00%
Underperform Votes
13
52.00%
Compass TherapeuticsOutperform Votes
25
73.53%
Underperform Votes
9
26.47%

PCB Bancorp has a net margin of 14.69% compared to PCB Bancorp's net margin of 0.00%. Compass Therapeutics' return on equity of 9.09% beat PCB Bancorp's return on equity.

Company Net Margins Return on Equity Return on Assets
PCB Bancorp14.69% 9.09% 0.93%
Compass Therapeutics N/A -28.67%-27.24%

In the previous week, PCB Bancorp had 1 more articles in the media than Compass Therapeutics. MarketBeat recorded 2 mentions for PCB Bancorp and 1 mentions for Compass Therapeutics. PCB Bancorp's average media sentiment score of 1.95 beat Compass Therapeutics' score of 1.02 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PCB Bancorp
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Compass Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

Compass Therapeutics beats PCB Bancorp on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMPX vs. The Competition

MetricCompass TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$137.59M$3.02B$5.20B$8.53B
Dividend YieldN/A2.08%2.80%3.97%
P/E Ratio-2.7821.56151.0717.73
Price / SalesN/A347.342,149.9579.09
Price / CashN/A174.4634.5433.62
Price / Book0.853.964.914.48
Net Income-$42.49M-$44.32M$109.42M$215.79M
7 Day Performance-0.99%-2.10%1.06%1.72%
1 Month Performance-9.09%3.82%8.81%7.67%
1 Year Performance-62.12%0.81%8.10%3.05%

Compass Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCB
PCB Bancorp
4.3586 of 5 stars
4.36 / 5 stars
$18.06
+4.6%
$17.00
-5.9%
+10.7%$246.39M$161.86M10.32272Upcoming Earnings
News Coverage
Positive News
TCBX
Third Coast Bancshares
1.7119 of 5 stars
1.71 / 5 stars
$23.89
+3.6%
$22.67
-5.1%
+28.1%$314.98M$274.75M11.77365Upcoming Earnings
AVXL
Anavex Life Sciences
4.099 of 5 stars
4.10 / 5 stars
$5.91
+7.8%
$40.00
+576.8%
-27.1%$500.22MN/A-11.8240News Coverage
FATE
Fate Therapeutics
4.6225 of 5 stars
4.62 / 5 stars
$4.56
+6.8%
$6.75
+48.0%
+2.2%$486.06M$63.53M-2.37181News Coverage
Positive News
PROK
ProKidney
1.9951 of 5 stars
2.00 / 5 stars
$2.14
+1.4%
$7.25
+238.8%
-81.6%$483.92MN/A-3.75163Gap Up
VYGR
Voyager Therapeutics
3.5393 of 5 stars
3.54 / 5 stars
$8.77
+4.8%
$18.00
+105.2%
-5.9%$455.27M$250.01M-175.36162News Coverage
Positive News
AURA
Aura Biosciences
0.8474 of 5 stars
0.85 / 5 stars
$9.15
+5.5%
$21.00
+129.5%
-22.5%$453.29MN/A-4.9250News Coverage
KYTX
Kyverna Therapeutics
0.7312 of 5 stars
0.73 / 5 stars
$9.71
-3.0%
$35.80
+268.7%
N/A$431.58M$7.03M0.0096Gap Up
OCGN
Ocugen
0.5972 of 5 stars
0.60 / 5 stars
$1.64
-1.2%
$4.67
+184.6%
+172.9%$427.21M$6.04M-6.5665Gap Down
CCCC
C4 Therapeutics
1.8777 of 5 stars
1.88 / 5 stars
$6.16
+2.2%
$8.71
+41.5%
+65.6%$414.90M$20.76M-2.60150News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:CMPX) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners